Valuation: Alamar Biosciences, Inc.

Market Cap 1.87B 1.64B 1.51B 1.4B 2.64B 180B 2.68B 18.06B 7.09B 88.18B 7.04B 6.89B 304B P/E 2026 *
-19.9x
P/E 2027 * -40.5x
Enterprise Value 1.69B 1.48B 1.37B 1.26B 2.38B 163B 2.42B 16.31B 6.4B 79.61B 6.36B 6.22B 274B EV / Sales 2026 *
14.9x
EV / Sales 2027 * 10.6x
Free-Float
73.32%
Yield 2026 *
-
Yield 2027 * -
1 day-1.28%
1 week+7.21%
Current month-0.15%
1 month+22.95%
1 week 25.06
Extreme 25.06
29.43
1 month 19.81
Extreme 19.81
29.43
Current year 18.84
Extreme 18.845
29.43
1 year 18.84
Extreme 18.845
29.43
3 years 18.84
Extreme 18.845
29.43
5 years 18.84
Extreme 18.845
29.43
10 years 18.84
Extreme 18.845
29.43
Manager TitleAgeSince
Chief Operating Officer 63 2018-07-31
Chief Tech/Sci/R&D Officer - 2020-12-31
Chief Executive Officer 62 2018-06-30
Director TitleAgeSince
Chairman 62 2018-06-30
Director/Board Member 64 2020-04-30
Date Insider Type Main position Quantity % Market Cap.
04-19Others

Director

140,612 -
04-19Others

Director

140,612 5.0951%
04-19Others

Director

206,781 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%+7.21% - - 1.87B
+1.05%+3.38%+25.56%+0.89% 198B
-6.78%-11.19%-26.52%+7.20% 134B
-0.55%+2.50%+0.66%-17.25% 141B
-4.52%-5.89%-59.14%-19.61% 63.36B
-1.85%-4.99%+15.09%-3.52% 51.87B
-3.57%-2.72%-25.44%-33.65% 43.77B
+0.87%+3.10%+12.59%+12.90% 38.18B
+0.85%+0.39%+23.74%+39.01% 36.96B
-5.59%-4.98%-17.18%-24.64% 28.05B
Average -1.25%-1.15%-5.63%-4.30% 73.78B
Weighted average by Cap. -1.25%-1.14%-2.17%-3.99%

Financials

2026 *2027 *
Net sales 113M 98.94M 91.46M 84.5M 159M 10.87B 162M 1.09B 428M 5.33B 425M 416M 18.34B 162M 142M 131M 121M 228M 15.56B 232M 1.56B 612M 7.62B 609M 595M 26.24B
Net income -73.16M -63.94M -59.1M -54.6M -103M -7.03B -105M -705M -277M -3.44B -275M -269M -11.85B -56.76M -49.61M -45.86M -42.37M -79.79M -5.45B -81.23M -547M -215M -2.67B -213M -209M -9.19B
Net Debt -182M -159M -147M -136M -256M -17.52B -261M -1.76B -689M -8.58B -685M -670M -29.53B -153M -133M -123M -114M -215M -14.67B -218M -1.47B -577M -7.18B -574M -561M -24.73B
Logo Alamar Biosciences, Inc.
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
Employees
222
Date Price Change Volume
26-07-14 US$27.05 -1.28% 222,945
26-07-13 US$27.40 -3.59% 402,369
26-07-10 US$28.42 +7.33% 246,959
26-07-09 US$26.48 +4.66% 192,071
26-07-08 US$25.30 +0.28% 165,636
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
27.05USD
Average target price
30.60USD
Spread / Average Target
+13.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMR Stock